Spyre Therapeutics, Inc.
SYRE
$14.67
$0.543.82%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 38.60% | 27.01% | 31.76% | -368.15% | -304.21% |
| Total Depreciation and Amortization | -- | -100.00% | -100.00% | -79.35% | -50.92% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -77.32% | -61.59% | -67.23% | 3,665.20% | 3,272.01% |
| Change in Net Operating Assets | 12.91% | -282.03% | -874.87% | 84.99% | 5.40% |
| Cash from Operations | -57.55% | -73.82% | -131.79% | -54.96% | -24.66% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -100.00% | -- | -- |
| Cash Acquisitions | -- | -100.00% | -100.00% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -215.71% | -248.09% | -795.89% | -578.81% | -296.16% |
| Cash from Investing | -225.93% | -268.76% | -751.50% | -571.65% | -290.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | 100.00% | 96.85% | 96.17% |
| Issuance of Common Stock | 187.07% | 83,477.24% | 498,938.89% | 107.76% | 96.84% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -42.56% | 20.84% | 20.84% | -- | -- |
| Repurchase of Preferred Stock | 97.19% | 97.19% | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 68.25% | -- | -- | -- | -- |
| Cash from Financing | 13.80% | 76.70% | 54.20% | 1,149.49% | 746.05% |
| Foreign Exchange rate Adjustments | -112.00% | -43.40% | -123.08% | 113.89% | 123.58% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -165.31% | -139.55% | -196.86% | 852.40% | 686.16% |